Ionis Pharmaceuticals reports Q3 2026 revenue of $243.0M, beating consensus

Ionis Pharmaceuticals reported Q3 2026 financial results with revenue of $243.0 million, surpassing the FactSet consensus estimate of $178.2 million. CEO Brett P. Monia highlighted three approvals for first-in-class medicines in 2026, two of which are Ionis-owned.

Detected & updated continuously · Source: Nebula